Cook launches esophageal balloon; MagForce snags ex-Fresenius CEO;

 @FierceMedDev: Editor's Corner: Germany's Epigenomics is betting its future on an early-detection colon cancer Dx. Feature | Follow @FierceMedDev

 @DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. Yesterday's story | Follow @DamianFierce

> Cook Medical is launching its Hercules esophageal balloon to treat patients with gastrointestinal strictures. News

> Germany's MagForce has appointed former Fresenius CEO Ben Lipps to be the company's next chief executive. Story

> Life Technologies ($LIFE) has licensed out its Invivofectamine technology to a Chinese drugmaker to develop siRNA treatments. More

> Castle Biosciences has launched DecisionDx-EC, a diagnostic designed to determine whether esophageal cancer patients will respond to chemoradiation therapy. Release

> Beckman Coulter won FDA clearance for a new myocardial infarction diagnostic test. More

> ArtVentive Medical won a CE mark for its self-expanding catheter. Article

> Becton Dickinson's ($BDX) growing bioscience unit launched a new cell analyzer, marketing the BD LSRFortessa X-20 as more compact than its competitors. Item

Biotech News

 @FierceBiotech: Join what is probably one of the fastest-growing LinkedIn groups in biotech, & learn the meaning of life... sciences. Join now | Follow @FierceBiotech

 @JohnCFierce: Man, oh man. Bluebird IPO busts out, raises $101M as biotech offerings turn red hot - $BLUE up 50%. News | Follow @JohnCFierce

 @RyanMFierce: W/ $BLUE out, DMD drug developer Prosensa moves up in the biotech IPO queue, sets terms for $60M deal: More | Follow @RyanMFierce

 @EmilyMFierce: This week's issue of FierceBiotechResearch is out: Alzheimer's drug restores links in brain and more: This week's news | Follow @EmilyMFierce

> Sarepta shares spike on upbeat results from DMD extension study. News

> NIH backs pharma giants and academics' projects to revive R&D castoffs. Article

> Analysis: AMA decision on obesity will boost drug R&D in a troubled field. Editor's corner

> Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround. Story

Pharma News

 @FiercePharma: More Novo Nordisk bad news: Loses Prandin patent fight in U.S. Circuit court, $200m sales at risk. Report | Follow @FiercePharma

 @EricPFierce: U.K. gets nervous on looming deadline for API certifications, outlines contingency plan. Yesterday's report | Follow @EricPFierce

> Biogen's impressive Tecfidera launch hits reimbursement, supply snags. Article

> Onglyza fails outcomes trial in a $1B hit for Bristol-Myers, AstraZeneca. Story

> Use prescription meds properly, save $200 billion a year. Report

Drug Delivery News

 @MichaelGFierce: Self-propelled, spinning 'nano-necklaces' could pinpoint drug delivery. More | Follow @MichaelGFierce

> BD, JDRF partner to join artificial pancreas race. More

> Capsugel launches Lipidex platform for greater oral stability, potency. Item

> Teva grabs MicroDose respiratory biz with inhaled delivery platform. Article

> Drug-carrying 'nanovolcanoes' make precise delivery structures. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.